Clinical Trials Logo

Clinical Trial Summary

The LFX453X2202 study tested the investigational drug LFX453 against placebo for safety, tolerability, and efficacy in treating genital warts in circumcised men, in parallel with an additional open label arm using imiquimod 5%. During the study the patients received either LFX453, placebo or active comparator and the tolerability and safety was assessed continuously through local tolerability assessments and adverse event recorded. Efficacy was clinical evaluations and lesion count. During the study biopsies were taken for analysis of pharmacokinetics and biomarkers. Blood samples were taken for safety, pharmacokinetics (PK), and biomarkers.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02482428
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date May 12, 2015
Completion date May 31, 2016

See also
  Status Clinical Trial Phase
Completed NCT02147353 - Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment N/A
Recruiting NCT01943630 - Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts Phase 2